Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
Varun Sasidharan NairSalman M ToorBassam R AliEyad ElkordPublished in: Expert opinion on therapeutic targets (2018)
These findings provide a rationale for combined targeting of STAT1 and STAT3 for the development of immune-based cancer therapies for down regulation of PD-L1 expression.